Form 4: Axogen Director Amy McBride Wendell Reports Stock Vesting

Director Amy McBride Wendell reports the vesting of 11,904 restricted stock units into common stock on September 1, 2024.

Summary

• Amy McBride Wendell, a director of Axogen, Inc., reported a transaction on September 1, 2024.
• 11,904 restricted stock units vested into common stock.
• Following the transaction, Wendell directly owns 102,899 shares of Axogen common stock.
• The vesting of the restricted stock units was part of an annual equity grant for service as a Director on the Axogen, Inc. Board of Directors.
• The equity grant was valued at $150,000 as of the grant date and vested on September 1, 2024, the one-year anniversary of the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of stock is a routine event and indicates continued service by the director. There are no explicitly negative aspects.

Positives

• The vesting of restricted stock units indicates continued service and alignment of interests between the director and the company.

Industry Context

Vesting of stock options and restricted stock units is a common practice for compensating and incentivizing board members and executives in publicly traded companies.

Comparison to Industry Standards

• Equity grants for board members vary significantly based on company size, industry, and individual contributions.
• Comparing Axogen's director compensation to similar-sized companies in the biotechnology or medical device sector would provide a better benchmark.
• Companies like Integra LifeSciences or Globus Medical could be considered for comparison, although specific compensation details for board members would need to be researched.

Stakeholder Impact

• The vesting of shares has a minor dilutive effect on existing shareholders.
• The director's increased stake aligns her interests further with those of shareholders.

Key Dates